Compare DexCom, Inc. (DXCM) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Mercadolibre Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Mercadolibre Inc trades at $1,889.85 (market cap $94.13B). The key difference: Mercadolibre Inc is far larger — about 3× DexCom, Inc.'s market cap, and Mercadolibre Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Mercadolibre Inc for 117 Days on average.
| DXCM | MELI | |
|---|---|---|
Market Cap | $31.86B | $94.13B |
Volume | 3,607,070 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $2.36K |
52-Week Low | $54.84 | $1.55K |
Typical Hold Time | 62 Days | 117 Days |
Enterprise Value | $31.32B | $101.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
MercadoLibre (MELI) trades at $1,856.66, down 0.86% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $28.89 billion in 2025, though net income margins dipped to 6.91%. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy business growth, while its fintech credit portfolio surged 75% in Q2 2026 to $16.4 billion.
Outlook remains positive with analyst consensus at 'Buy' and a $2,170 price target, but risks include profit margin pressure and macroeconomic headwinds in Latin America. The stock's high P/E of 50.51 suggests growth expectations are priced in, requiring sustained execution to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
